GSE202350
IFNa primes cancer cells for Fusicoccin-induced cell death via 14-3-3 PPI stabilization
The natural product family of the fusicoccanes (FCs) has been shown to display anti-cancer activity, especially when combined with established therapeutic agents. FCs stabilize 14-3-3 protein-protein interactions (PPIs). Here, we tested combinations of a small library of FCs with interferon a (IFNa) on different cancer cell lines and report a proteomics approach to identify the specific 14-3-3 PPIs that are induced by IFNa and stabilized by FCs in OVCAR-3 cells. Among the identified 14-3-3 target proteins are THEMIS2, receptor interacting protein kinase 2 (RIPK2), EIF2AK2, and several members of the LDB1 complex. Biophysical and structural biology studies confirm these 14-3-3 PPIs as physical targets of FC stabilization, and transcriptome as well as pathway analyses suggest possible explanations for the observed synergistic effect of IFNa/FC treatment on cancer cells. This study elucidates the polypharmacological effects of FCs in cancer cells and identifies potential targets from the vast interactome of 14-3-3s for therapeutic intervention in oncology. Overall design: Comparative gene expression profiling analysis of RNA-seq data for OVCAR-3 cells treated with FC-A, IFNa and combination of FC-A and IFNa.